Amicus Therapeutics, Inc. provided earnings guidance for the full year 2023. For the full-year 2023, the Company expected total revenue growth between 14 and 18% at CER.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.41 USD | -0.76% |
|
+3.89% | -26.64% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.64% | 3.08B | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2023